Related Experiment Video
Updated: Dec 24, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
AMPK activation ameliorates fine particulate matter-induced hepatic injury
Liying Song1, Shuo Jiang1, Kun Pan1
1Department of Environmental Health, School of Public Health and the Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China.
Abstract:
Both the epidemiological and animal experimental studies have reported the association between PM2.5 and respiratory, cardiovascular, and metabolic diseases. However, the study linking PM2.5 and hepatic injury is few, and the relative mechanism has not been fully elucidated. Thirty-two 6-week-old male C57BL/6 mice were exposed to filtered air (FA) or concentrated PM2.5 for 12 weeks using Shanghai Meteorological and Environmental Animal Exposure System ("Shanghai-METAS"), respectively. At week 11, the mice began to be treated with intraperitoneal injection of normal 0.9% saline or AMPK activator (AICAR). The mRNA levels of IL-6 and TNF-α, and protein expressions of AMPK, GLUT4, NF-κB, p38MAPK, ERK, and JNK in the liver and UCP-1 in brown adipose tissue (BAT) were measured. Meanwhile, histopathological examination both in the liver and BAT was performed to evaluate the histopathological changes. PM2.5 exposure induced steatosis, hepatocyte ballooning, lobular and portal inflammation in the liver, and the brown adipocyte swelling in BAT. The results found that PM mice displayed higher IL-6, TNF-α, NF-κB, and JNK expression and lower AMPK, GLUT4, and UCP-1 when compared with FA mice. The AICAR injection upregulated the expressions of GLUT4 in the liver of PM-AIC mice when compared with the PM mice. However, there were no significant effects of AICAR on histopathological condition. The current study showed that ambient PM2.5 exposure might induce the hepatic injury along with the lipid metabolism disorder in BAT. AMPK activation can ameliorate most of the harmful effects and might become the potential target for treating PM2.5-induced hepatic injury.
Insights
Exposure to fine particulate matter (PM2.5) can harm the liver and disrupt fat metabolism. Activating AMP-activated protein kinase (AMPK) may offer protection against these PM2.5-induced injuries.
Area of Science:
- Environmental Health
- Toxicology
- Metabolic Disease
Background:
- Epidemiological and animal studies link PM2.5 exposure to respiratory, cardiovascular, and metabolic diseases.
- Research on PM2.5-induced hepatic injury and its mechanisms remains limited.
Purpose of the Study:
- To investigate the effects of PM2.5 exposure on hepatic injury and lipid metabolism in brown adipose tissue (BAT).
- To explore the potential therapeutic role of AMP-activated protein kinase (AMPK) activation in mitigating PM2.5-induced damage.
Main Methods:
- Male C57BL/6 mice were exposed to filtered air (FA) or concentrated PM2.5 for 12 weeks.
- Mice received intraperitoneal injections of saline or an AMPK activator (AICAR) during the final week.
- Liver and BAT tissues were analyzed for gene and protein expression, and histopathological changes were assessed.
Main Results:
- PM2.5 exposure induced liver steatosis, inflammation, and hepatocyte ballooning, along with BAT swelling.
- PM2.5-exposed mice showed increased IL-6, TNF-α, NF-κB, and JNK, and decreased AMPK, GLUT4, and UCP-1.
- AICAR treatment upregulated hepatic GLUT4 expression in PM2.5-exposed mice but did not significantly alter histopathology.
Conclusions:
- Ambient PM2.5 exposure may cause hepatic injury and disrupt lipid metabolism in BAT.
- AMPK activation shows potential in ameliorating PM2.5-induced harmful effects, suggesting it as a therapeutic target.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
07:35Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
Published on: December 10, 2021
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment